AbbVie again hikes guidance as it eyes neuro, obesity and PD-1xVEGF dealsnews2025-07-31T15:34:38+00:00July 31st, 2025|Endpoints News|
Bristol Myers raises revenue guidance for the year, prepares for major Cobenfy readoutsnews2025-07-31T15:16:10+00:00July 31st, 2025|Endpoints News|
Prime Medicine is selling $125M in stock; Nuvectis stops work on ovarian cancer drugnews2025-07-31T14:46:10+00:00July 31st, 2025|Endpoints News|
ImmuneOnco, Instil Bio’s PD-L1xVEGF posts encouraging mid-stage datanews2025-07-31T14:42:44+00:00July 31st, 2025|Endpoints News|
Endpoints livestream: Is China’s biotech boom unstoppable?news2025-07-31T14:33:56+00:00July 31st, 2025|Endpoints News|
Ignoring China’s biotech industry is no longer an option. It’s a recipe for disasternews2025-07-31T14:00:23+00:00July 31st, 2025|Endpoints News|
Trump administration to launch a unified health records systemnews2025-07-31T13:55:51+00:00July 31st, 2025|Endpoints News|
WuXi AppTec targets $981M raise; Stockpiling leads to Leqembi sales jumpnews2025-07-31T13:32:03+00:00July 31st, 2025|Endpoints News|
Alnylam sharply raises sales projections for Amvuttra group on heels of new approvalnews2025-07-31T12:00:29+00:00July 31st, 2025|Endpoints News|
Radella hopes muscle-sparing obesity approach will make it stand outnews2025-07-31T12:00:16+00:00July 31st, 2025|Endpoints News|
